Marker Therapeutics
MRKR on Nasdaq. Market value $18m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 35 funds in all.
Sold out this quarter
- Matrix Asset AdvisorsDavid KatzSold out
Largest holders overall
- NEA Management Company$2m
- Blue Owl Capital Holdings LP$814,748
- Vanguard Capital Management$626,468Added
- Aisling Capital Management LP$478,293
- Renaissance Technologies$366,652Added
- Geode Capital Management$205,558Cut
- Osaic Holdings$165,590Added
- Vanguard Fiduciary Trust$128,285
- LPL Financial$122,226
- Concurrent Investment Advisors$99,906New
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- Blue Owl Capital Holdings LPPassive investor10.0%+4.8 ptsSince 31 March 2025
- New Enterprise Associates 16, L.P.Passive investorat least 9.9%−2.7 pts(filed with 9 related holders)Since 13 November 2025
What they said
NEA 16 acquired the NEA 16 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 16 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer,…
Read the filing - Alyeska Investment Group, L.P.Passive investorat least 9.9%−0.1 pts(filed with 2 related holders)Since 30 September 2025
- John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017Passive investorSold down below 5%Since 19 August 2025
What they said
The information set forth in Item 4 of Amendment No. 1 is incorporated herein by reference.
Read the filing
| Holder | Stake | Since | |
|---|---|---|---|
Blue Owl Capital Holdings LP Passive investor | 10.0%+4.8 pts | 31 March 2025 | |
New Enterprise Associates 16, L.P. Passive investor | at least 9.9%−2.7 pts (filed with 9 related holders) | 13 November 2025 | What they saidNEA 16 acquired the NEA 16 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 16 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer,… Read the filing |
Alyeska Investment Group, L.P. Passive investor | at least 9.9%−0.1 pts (filed with 2 related holders) | 30 September 2025 | |
John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 Passive investor | Sold down below 5% | 19 August 2025 | What they saidThe information set forth in Item 4 of Amendment No. 1 is incorporated herein by reference. Read the filing |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Marker Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 18 Mar 2026, plus the 10-Q filed 14 Aug 2026 and 2 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”
Show the full paragraph
Based on the Company’s lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of June 30, 2026, the Company anticipates that it will be able to fund its operating expenses and capital expenditure requirements into the second quarter of 2027, assuming no additional grant funds are received, either from new grants or from existing awarded grants. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.
From the 10-Q filed 14 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.